P030052/S030: UroVysion Bladder Cancer Kit
FDA’s recorded scope: implementation of a secondary packaging process
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 1 FDA record to the applicant name Abbott Molecular. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Feb 18, 2026 to Feb 18, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
The largest PMA family in this collection is P030052, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 1300 E Touhy Ave., Des Plaines, IL, 60018. Recorded on P030052/S030, decision dated Feb 18, 2026.
FDA’s recorded scope: implementation of a secondary packaging process
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
UroVysion Bladder Cancer KitP030052/S030 | Abbott Molecular | PMA supplement | Feb 18, 2026 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.